All AbMole products are for research use only, cannot be used for human consumption.
LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. BMPs induce Smad1/5/8 plus non-Smad pathways, such as MAPK and Akt. BMP signaling pathway is the key regulators of cell fate decisions during embryogenesis and tissue homeostasis. LDN-193189 inhibits ectopic ossification and a potential agent in the treatment of NSCLC lung tumors, showing significant in vivo clinical utility. In addition, it inhibits the activation of p38, ERK1/2 and Akt in C2C12 cells. LDN-193189 only weakly inhibits ALK4, ALK5, and ALK7. LDN-193189 affects not only the Smad but also the non-Smad signalling pathways induced by either BMP2, BMP6 or GDF5.
J Cell Mol Med. 2025 May 12;29(9):e70601.
The Potential Hepatocyte Differentiation Targets and MSC Proliferation by FH1
LDN-193189 purchased from AbMole
Theriogenology. 2024 Mar 15;219:65-74.
Growth differentiation factor 9 regulates the expression of estrogen receptors via Smad2/3 signaling in goat cumulus cells
LDN-193189 purchased from AbMole
Patent. CN119220610A 2024 Dec 31.
Patent. CN119220610A
LDN-193189 purchased from AbMole
Ann Transl Med. 2021 Jul;9(13):1087.
Functional hit 1 (FH1)-based rapid and efficient generation of functional hepatocytes from human mesenchymal stem cells: a novel strategy for hepatic differentiation
LDN-193189 purchased from AbMole
 |
Source | J Biol Chem (2015). Figure 4. LDN-193189 |
| Method | immunoblotting | |
| Cell Lines | C2C12 cells | |
| Concentrations | 5 μM | |
| Incubation Time | 30 min | |
| Results | Pretreatment with dorsomorphin or LDN-193189 led to reduced levels of phosphorylated Smad2/3 following GDF8 stimulation (Fig. 4A), which were comparable with their effects on BMP2-induced phosphorylation of Smad1/5 (Fig. 4B), whereas there was no effect on TGF- induced Smad2/3 signals (Fig. 4A). |
 |
Source | J Biol Chem (2015). Figure 2. LDN-193189 |
| Method | immunoblotting | |
| Cell Lines | C2C12 cells | |
| Concentrations | 0.5 μM | |
| Incubation Time | 30 min | |
| Results | A similar effect of dorsomorphin and LDN-193189 treatment was observed in undifferentiated primary human myoblasts as well as in the mouse myoblast cell line C2C12 |
| Cell Experiment | |
|---|---|
| Cell lines | C2C12 cells |
| Preparation method | Alkaline phosphatase activity We seeded C2C12 cells into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. We treated the wells in quadruplicate with BMP ligands and LDN-193189 or vehicle. We collected the cells after 6 d in culture in 50 μl Tris-buffered saline and 1% Triton X-100. We added the lysates to p-nitro-phenylphosphate reagent in 96-well plates for 1 h and then evaluated alkaline phosphatase activity (absorbance at 405 nm). We measured cell viability and quantity by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements. |
| Concentrations | 0,2,8,31,125,500nM |
| Incubation time | 6 days |
| Animal Experiment | |
|---|---|
| Animal models | C57BL/6 mouse FOP model |
| Formulation | unknown |
| Dosages | 3 mg /kg every 12 h |
| Administration | intraperitoneally |
| Molecular Weight | 406.48 |
| Formula | C25H22N6 |
| CAS Number | 1062368-24-4 |
| Solubility (25°C) | DMSO 4.5 mg/mL (ultrasonic and warming and adjust pH to 2 with 1M HCl) Water ~1 mg/mL (warming and adjust pH to 2 with HCl) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ALK Products |
|---|
| AP26113 (Brigatinib)
AP26113 (Brigatinib) is a highly potent ALK inhibitor with IC50 of 0.6 nM. |
| X-376
X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM. |
| SB431542
SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). |
| RepSox (ALK5 Inhibitor II)
RepSox (ALK5 Inhibitor II) is a potent and ATP-competitive inhibitor of the TGF-β type I receptor ALK5 (IC50 values are 0.004 and 0.023 μM for ALK5 autophosphorylation and ALK5 binding respectively). |
| GSK1838705A
GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
